Clinical Significance of Anti-dsDNA Antibody,Complement C3 and Other Laboratory Indicators in the Diagnosis of Renal Injury in Systemic Lupus Erythematosus
-
摘要:
目的 探讨抗dsDNA抗体、补体C3及其他实验室指标的水平在系统性红斑狼疮(systemic lupus erythematosus,SLE)合并肾损伤患者中的临床应用价值。 方法 回顾性分析296例SLE患者的病历资料,比较SLE合并肾损伤组和未合并肾损伤组的自身抗体及其他实验室指标水平的差异,寻找SLE肾损伤的免疫学指标。 结果 SLE合并肾损伤组血清抗dsDNA、抗核小体及抗组蛋白等抗体的阳性率显著高于未合并肾损伤组,血清肾功能指标如尿素、肌酐及尿酸,电解质如钾、氯及钙离子等水平显著高于未合并肾损伤组,免疫球蛋白IgG、IgA及补体C3等水平显著低于未合并肾损伤组,差异有统计学意义(P < 0.05)。 结论 抗dsDNA、抗核小体、抗组蛋白等自身抗体、补体C3及多项实验室指标可能与SLE患者肾损伤相关。 Abstract:Objective To investigate the clinical application value of anti-dsDNA antibody, complement C3 and other laboratory indicators in patients with systemic lupus erythematosus (SLE) with renal injury. Methods The clinical data of 296 SLE patients were retrospectively analyzed. The differences of autoantibodies and other laboratory indicators between SLE with renal injury group and without renal injury group were compared, and the immunological indicators of SLE renal injury were found. Results The positive rates of serum anti-dsDNA, anti-nucleosome and anti-histone antibodies in SLE with renal injury group were significantly higher than those in without renal injury group, serum renal function indexes such as urea, creatinine and uric acid, electrolytes such as potassium, chlorine and calcium ion were significantly higher than those in without renal injury group, and the levels of immunoglobulin IgG, IgA and complement C3 were significantly lower than those in without renal injury group (P < 0.05). Conclusion Anti-dsDNA, anti-nucleosome, anti-histone autoantibodies, complement C3 and other laboratory indicators may be associated with renal injury in SLE patients. -
Key words:
- Systemic lupus erythematosus /
- Renal injury /
- Autoantibody /
- Anti-dsDNA antibody /
- C3
-
表 1 两组自身抗体阳性率比较[n(%)]
Table 1. Comparison of the positive rate of autoantibodies between the two groups [n(%)]
检测指标 SLE合并肾损伤组阳性例数 未合并肾损伤组阳性例数 χ2 P ANA抗体(n = 296) 73(98.6) 215(96.8) 0.171 0.679 抗dsDNA抗体(n = 296) 42(56.8) 73(32.9) 13.315 0.000 抗核小体抗体(n = 224) 41(69.5) 81(49.1) 7.293 0.007 抗组蛋白抗体(n = 224) 40(67.8) 81(49.1) 6.122 0.013 抗SmD1抗体(n = 296) 42(56.8) 124(55.9) 0.018 0.892 抗U1-RNP抗体(n = 296) 25(33.8) 107(48.2) 4.667 0.031 抗SSA-RO 60KD抗体(n = 296) 51(68.9) 139(62.6) 0.960 0.327 抗SSA-RO 52KD抗体(n = 296) 28(37.8) 101(45.5) 1.324 0.250 抗SSB-La抗体(n = 296) 16(21.6) 54(24.3) 0.225 0.636 表 2 两组血液学检查指标水平比较[M(P25,P75)]
Table 2. Comparison of hematological indexes between the two groups [M(P25,P75)]
检测指标 SLE合并肾损伤组(n = 74) 未合并肾损伤组(n = 222) Z/t P 白细胞(×109/L) 5.45(3.90,7.42) 4.52(3.18,5.91) −2.536 0.011 中性粒细胞(×109/L) 4.08(2.50,5.61) 2.97(1.85,4.33) −3.443 0.001 淋巴细胞(×109/L) 1.01(0.57,1.48) 1.05(0.67,1.45) −0.438 0.661 红细胞(×1012/L) 3.75(3.16,4.21) 4.02(3.54,4.48) −2.523 0.012 血红蛋白(g/L) 106(89,124.25) 115(97,130) −2.262 0.024 血小板[×109/L,($\bar x\pm s $)] 173.05 ± 83.72 187.19 ± 82.96 −1.267 0.206 表 3 两组其他实验室指标水平比较[M(P25,P75)]
Table 3. Comparison of other laboratory indexes between the two groups [M(P25,P75)]
检测指标 SLE合并肾损伤组(n = 74) 未合并肾损伤组(n = 222) Z P 总蛋白(g/L) 60.15(48.38,68.63) 67.30(58.98,73.68) −4.357 0.000 白蛋白(g/L) 27.05(22.33,34.10) 33.95(27.48,37.90) −5.001 0.000 球蛋白(g/L) 30.90(24.15,36.23) 32.05(27.40,38.30) −2.052 0.04 ALT(IU/L) 11.85(7.68,21.28) 15.40(10.59,26.05) −2.545 0.011 AST(IU/L) 18.10(13.28,27.65) 19.95(14.60,28.58) −1.368 0.171 总胆红素(μmol/L) 5.65(3.38,7.53) 6.65(4.70,9.88) −2.865 0.004 直接胆红素(μmol/L) 2.35(1.50,3.28) 3.00(2.18,4.70) −3.274 0.001 间接胆红素(μmol/L) 3.05(1.80,4.43) 3.40(2.20,5.33) −2.127 0.033 尿素(μmol/L) 6.78(4.24,11.88) 4.39(3.11,6.51) −4.686 0.000 肌酐(μmol/L) 79.15(59.43,144.58) 62.45(53.68,80.15) −4.235 0.000 尿酸(μmol/L) 391(301.55,506.33) 303.60(248.80,368.65) −4.909 0.000 钾(mmol/L) 3.99(3.76,4.54) 3.74(3.51,4.00) −5.034 0.000 钠(mmol/L) 139.55(136.55,142.33) 140.15(137.90,142.73) −1.384 0.166 氯(mmol/L) 106.85(104.05,110.08) 105.70(103.60,108.03) −2.059 0.039 钙(mmol/L) 2.05(1.95,2.18) 2.17(2.06,2.26) −3.969 0.000 IgG(g/L) 12(8.10,15.50) 13.80(10.10,18.80) −2.564 0.010 IgM(g/L) 0.96(0.69,1.41) 1.02(0.64,1.52) −0.542 0.588 IgA(g/L) 2.13(1.39,3.22) 2.22(1.58,3.29) −0.878 0.38 C3(g/L) 0.50(0.31,0.70) 0.65(0.43,0.86) −3.412 0.001 C4(g/L) 0.08(0.04,0.14) 0.10(0.05,0.16) −1.789 0.074 -
[1] Arvind K,Caroline G,K C M,et al. Systemic lupus erythematosus[J]. Nature reviews. Disease Primers,2016,2(2):16039. [2] Oku K,Atsumi T. Systemic lupus erythematosus:nothing stale her infinite variety[J]. Mod Rheumatol,2018,28(5):758-765. doi: 10.1080/14397595.2018.1494239 [3] Hahn B H,McMahon M A,Wilkinson A,et al. American college of rheumatology guidelines for screening,treatment,and management of lupus nephritis[J]. Arthritis Care Res(Hoboken),2012,64(6):797-808. doi: 10.1002/acr.21664 [4] Maria N I,Davidson A. Protecting the kidney in systemic lupus erythematosus:from diagnosis to therapy[J]. Nature Reviews Rheumatology,2020,16(5):255-267. doi: 10.1038/s41584-020-0401-9 [5] Yung S,Chan T M. Anti-dsDNA antibodies and resident renal cells-Their putative roles in pathogenesis of renal lesions in lupus nephritis[J]. Clin Immunol,2017,185(185):40-50. [6] 中华医学会风湿病学分会. 系统性红斑狼疮诊断及治疗指南[J]. 中华风湿病学杂志,2010,14(5):342-346. doi: 10.3760/cma.j.issn.1007-7480.2010.05.016 [7] Yung S,Chan T M. Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis:Getting to know the unknown[J]. Clinical & developmental immunology,2012,12:139313-139365. [8] Kwon O C,Lee J S,Ghang B,et al. Predicting eventual development of lupus nephritis at the time of diagnosis of systemic lupus erythematosus[J]. Semin Arthritis Rheum,2018,48(3):462-466. doi: 10.1016/j.semarthrit.2018.02.012 [9] Hanly J G,Su L,Farewell V,et al. Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus[J]. Journal of Immunological Methods,2010,358(1):75-80. [10] Jain D,Aggarwal H K,Kaverappa V,et al. Anti-dsDNA negative and anti-Ro positive lupus nephritis:a report of a rare case[J]. Reumatismo,2014,65(6):302-306. doi: 10.4081/reumatismo.2013.706 [11] Linnik M D,Hu J Z,Heilbrunn K R,et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus[J]. Arthritis and Rheumatism,2005,52(4):1129-1137. doi: 10.1002/art.20980 [12] Yang J,Xu Z,Sui M,et al. Co-Positivity for Anti-dsDNA,-Nucleosome and -Histone antibodies in lupus nephritis is indicative of high serum levels and severe nephropathy[J]. PLoS One,2015,10(10):e140441. [13] Sui M,Lin Q,Xu Z,et al. Simultaneous positivity for anti-DNA,anti-nucleosome and anti-histone antibodies is a marker for more severe lupus nephritis[J]. J Clin Immunol,2013,33(2):378-387. doi: 10.1007/s10875-012-9825-6 [14] Yung S,Yung S,Chan T M,et al. Molecular and immunological basis of tubulo-interstitial injury in lupus nephritis:A comprehensive review[J]. Clinical Reviews in Allergy & Immunology,2017,52(2):149-163. [15] 平利峰,王晓磊,孙凤艳,等. 狼疮性肾炎患者血清自身免疫抗体水平变化及相关性研究[J]. 疑难病杂志,2019,18(3):289-292. doi: 10.3969/j.issn.1671-6450.2019.03.017 [16] R L,van Bruggen M C,B O,et al. Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus:effects of disease progression and lipopolyssacharide administration[J]. Arthritis and Rheumatism,2001,44(6):1320-1330. doi: 10.1002/1529-0131(200106)44:6<1320::AID-ART224>3.0.CO;2-X [17] Tak-Mao C,Kok-Hung L J,Kar-Nung H S,et al. Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus[J]. Journal of the American Society of Nephrology:JASN,2002,13(5):1219-1229. doi: 10.1097/01.ASN.0000014223.71109.13 [18] Grootscholten C,van Bruggen M C J,van der Pijl J W,et al. Deposition of nucleosomal antigens(histones and DNA)in the epidermal basement membrane in human lupus nephritis[J]. Arthritis & Rheumatism,2003,48(5):1355-1362. [19] 曾繁明. 系统性红斑狼疮肾损伤患者尿微量蛋白和免疫球蛋白水平的变化及意义[J]. 临床合理用药杂志,2020,13(5):141-142. [20] Moroni G,Radice A,Giammarresi G,et al. Are laboratory tests useful for monitoring the activity of lupus nephritis A 6-year prospective study in a cohort of 228 patients with lupus nephritis[J]. Ann Rheum Dis,2009,68(2):234-237. doi: 10.1136/ard.2008.094508 [21] 兰访,韦慧萍,朱璇,等. 系统性红斑狼疮补体C3、C4水平与其他相关实验指标的相关性研究[J]. 广西医科大学学报,2016,33(6):989-992.